Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX) reported financial results for Q1 2024, highlighting a net loss decrease compared to 2023. The company is exploring strategic alternatives to maximize shareholder value, potentially leading to dissolution. The Board adopted a Rights Agreement to protect stockholder interests. Galera had $13.5 million in cash as of March 31, 2024, expected to fund operations into Q3 2025.
Net loss decreased to $(4.4) million in Q1 2024 from $(17.7) million in Q1 2023.
The company is exploring strategic alternatives to maximize shareholder value.
The adoption of a Rights Agreement aims to protect stockholder interests and enable fair decision-making by the Board.
Galera had $13.5 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into Q3 2025.
The company reported a decrease in research and development expenses, indicating a cessation of clinical trial activity and product development.
A decreased net loss may be attributed to cost-cutting measures such as workforce reduction and halting clinical development.
Insights
Examining the reduction in research and development (R&D) and general and administrative (G&A) expenses, it appears Galera Therapeutics is taking significant cost-cutting measures. The drop in R&D expenses from
On the G&A front, expenditures have more than halved, plummeting from
The cash position, sufficient to carry operations into the third quarter of 2025, provides a cushion during the strategic review process. Yet, investors should remain vigilant regarding the outcome of this process, which is likely to determine the trajectory of the share price.
The strategic review process mentioned signals uncertainty regarding Galera's future direction. Historically, such processes can lead to a range of outcomes, from revitalization through partnerships to a total sale or wind-down of the company. The adoption of a stockholder rights agreement indicates a protective stance against potential hostile takeovers, suggesting that management is primed to safeguard shareholder value during this vulnerable transitional period.
While the possibility of 'strategic transactions' to advance avasopasem's development could intrigue, the mention of potential dissolution raises red flags about the company's stability. From an industry insight perspective, the market tends to view such uncertainty as a risk, which could impact investor sentiment and stock volatility in the near term.
The adoption of the Rights Agreement by Galera's Board in the context of 'recent accumulations' of the company's stock is a classic defensive maneuver. This 'poison pill' strategy is intended to deter or complicate takeovers by making them more expensive, thereby granting the Board more control over the M&A process. It's a double-edged sword, though, as it can also be perceived as a barrier to shareholder activism, potentially stifling the stock price.
Investors generally prefer clarity and decisive action, so the absence of a fixed timeline for the strategic review might be received with caution. Transparency and regular updates could help mitigate investor concerns during this period of strategic ambiguity.
Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.
"Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera’s President and CEO. “Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path for avasopasem. The process could ultimately culminate in the dissolution of the Company.”
General Corporate Updates
- Galera remains actively engaged with Stifel, Nicolaus & Company, Inc. to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics. The Company has not set a fixed timeline for completing this evaluation process and does not intend to disclose further updates unless and until it is determined that further disclosure is appropriate or necessary.
- On May 3, 2024, the Company announced that its Board of Directors (the “Board”) unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock, and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in Galera and to protect the interests of the Company and its stockholders by reducing the likelihood that any person or group gains control of Galera without paying an appropriate control premium. In addition, the Rights Agreement provides the Board with time to make informed decisions that are in the best long-term interests of Galera and its stockholders. It does not deter the Board from considering any offer or proposal that is fair and otherwise in the best interest of Galera stockholders.
First Quarter 2024 Financial Highlights
- Research and development expenses were
$1.5 million in the first quarter of 2024, compared to$7.3 million for the same period in 2023. The decrease was primarily attributable to a decrease in avasopasem and rucosopasem development costs. The Company has ceased all clinical trial activity and suspended the clinical development of its product candidates as it explores potential strategic alternatives. - General and administrative expenses were
$3.1 million in the first quarter of 2024, compared to$6.6 million for the same period in 2023. The decrease was primarily attributable to the cessation of avasopasem commercial preparations and medical affairs activities and reduced personnel-related expenses due to the workforce reduction announced in August 2023. - Galera reported a net loss of
$(4.4) million , or$(0.08) per share, for the first quarter of 2024, compared to a net loss of$(17.7) million , or$(0.50) per share, for the same period in 2023. - As of March 31, 2024, Galera had cash and cash equivalents of
$13.5 million . Galera expects that its existing cash and cash equivalents will enable Galera to fund its operating expenses and capital expenditure requirements into the third quarter of 2025.
About Galera Therapeutics
Galera Therapeutics, Inc. is a biopharmaceutical company that was historically focused on developing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (avasopasem) was being developed for radiation-induced and cisplatin-related toxicities. The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of severe oral mucositis induced by radiotherapy. The Company’s second product candidate, rucosopasem manganese (rucosopasem), was being developed to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem has been granted orphan drug designation and orphan medicinal product designation by the FDA and EMA, respectively, for the treatment of pancreatic cancer. Galera is headquartered in Malvern, PA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: Galera’s pursuit of strategic alternatives and the ability of any such strategic alternative to provide stockholder value, including a potential development path for avasopasem; the potential safety and efficacy of Galera’s product candidates and their regulatory and clinical development; Galera’s ability to fund its operating expenses and capital expenditure requirements into the third quarter of 2025; and Galera’s ability to achieve its goal of transforming radiotherapy in cancer treatment with its selective dismutase mimetics. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Galera’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: Galera’s limited operating history; anticipating continued losses for the foreseeable future; needing substantial funding and the ability to raise capital; Galera’s dependence on avasopasem manganese (GC4419); uncertainties inherent in the conduct of clinical trials; difficulties or delays enrolling patients in clinical trials; the FDA’s acceptance of data from clinical trials outside the United States; undesirable side effects from Galera’s product candidates; risks relating to the regulatory approval process; failure to capitalize on more profitable product candidates or indications; ability to receive or maintain Breakthrough Therapy, Orphan Drug or Fast Track Designations for product candidates; failure to obtain regulatory approval of product candidates in the United States or other jurisdictions; ongoing regulatory obligations and continued regulatory review; risks related to commercialization; risks related to competition; ability to retain key employees; risks related to intellectual property; inability to maintain collaborations or the failure of these collaborations; Galera’s reliance on third parties; the possibility of system failures or security breaches; liability related to the privacy of health information obtained from clinical trials and product liability lawsuits; environmental, health and safety laws and regulations; Galera may not be able to enter into any desired strategic alternative or partnership on a timely basis, on acceptable terms, or at all; if Galera is unable to secure additional funding or enter into any desired strategic alternative or partnership, it may need to cease operations; risks related to ownership of Galera’s common stock; the possibility of Galera’s common stock being delisted from The Nasdaq Global Market; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in Galera’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) and Galera’s other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statements speak only as of the date of this press release and are based on information available to Galera as of the date of this release, and Galera assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Galera Therapeutics, Inc. | |||||||
| Consolidated Statements of Operations | |||||||
| (unaudited, in thousands except share and per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 1,488 | $ | 7,272 | |||
| General and administrative | 3,089 | 6,609 | |||||
| Loss from operations | (4,577 | ) | (13,881 | ) | |||
| Other income (expense), net | 196 | (3,829 | ) | ||||
| Net loss | $ | (4,381 | ) | $ | (17,710 | ) | |
| Net loss per share of common stock, basic and diluted | $ | (0.08 | ) | $ | (0.50 | ) | |
| Weighed average common shares outstanding, basic and diluted | 54,392,170 | 35,196,134 | |||||
| Galera Therapeutics, Inc. | |||||||
| Selected Consolidated Balance Sheet Data | |||||||
| (unaudited, in thousands) | |||||||
| March 31, | December 31, | ||||||
| 2024 | 2023 | ||||||
| Cash and cash equivalents | $ | 13,466 | $ | 18,257 | |||
| Total assets | 19,651 | 26,141 | |||||
| Total current liabilities | 2,013 | 4,957 | |||||
| Total liabilities | 154,342 | 157,326 | |||||
| Total stockholders' deficit | (134,691 | ) | (131,185 | ) | |||
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Strategic Communications
646-378-2946
wwindham@soleburystrat.com
Media Contact:
Timothy Biba
Solebury Strategic Communications
646-378-2927
tbiba@soleburystrat.com
FAQ
What were Galera Therapeutics' net loss and earnings per share for Q1 2024?
What is Galera Therapeutics' stock symbol?
How much cash did Galera Therapeutics have as of March 31, 2024?
